ArriVent Biopharma paid $47m to license MRG007, a Phase 1-ready gastrointestinal cancer therapy developed by Shanghai’s Lepu Biopharma. The antibody drug conjugate has not had its target disclosed but ArriVent said studies showed it had “best-in-class potential”, and suggested it could be a drug that targets claudin 18.2. ArriVent said MRG007 displayed strong anti-tumour action in preclinical models, with the first submissions expected in H1 2022.
Linux Kernel KSMBD Flaw Lets Remote Attackers Drain Server Resources
A critical vulnerability in the Linux kernel’s KSMBD implementation has been discovered that allows remote attackers to completely exhaust server connection resources through a simple
